Ozempic: adverse event reports filed with FDA

52,881

reports as suspect product

0.3% of all reports · about 4,736 a year

21,704

reports, 12 months to June 2026

9,425 in the 12 months before

48.8%

marked serious by the reporter

28% across the class

1.4%

record death among outcomes, as reported

747 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Ozempic reports recording the termmedian drug in glp-1 receptor agonist

1. Nauseafeeling sick16.7%8,820
2. Off label useused for a purpose or in a way not on the label11.5%6,107
3. Vomitingbeing sick10.9%5,772
4. Diarrhoealoose or frequent stools9.8%5,169
5. Decreased appetitereduced appetite8%4,243
6. Constipationconstipation7.8%4,099
7. Weight decreasedweight loss7%3,686
8. Impaired gastric emptying6.4%3,390
9. Product use in unapproved indicationused for a purpose not on the label5.7%3,022
10. Wrong technique in product usage processthe product was used in the wrong way5.1%2,703
11. Abdominal pain upperupper stomach pain4.9%2,571
12. Blood glucose increasedraised blood sugar reading4.3%2,289
13. Weight increasedweight gain4.1%2,155
14. Headachehead pain3.9%2,044
15. Abdominal painstomach or belly pain3.7%1,944
16. Inappropriate schedule of product administrationthe product was taken at the wrong times3.7%1,939
17. Dizzinesslight-headedness or unsteadiness3.4%1,793
18. Fatiguetiredness3.3%1,761
19. Dehydrationdehydration3.1%1,652
20. Abdominal distensiona bloated abdomen2.8%1,463
21. Dyspepsiaindigestion2.7%1,433
22. Astheniaweakness or lack of energy2.6%1,383
23. Malaisegeneral feeling of being unwell2.6%1,355
24. Illness2.5%1,330
25. Abdominal discomfortstomach discomfort2.3%1,194
26. Visual impairmentreduced vision2.2%1,180
27. Pancreatitisinflammation of the pancreas2.1%1,091
28. Intestinal obstructiona blocked bowel2.1%1,085
29. Blood glucose decreasedlow blood sugar reading1.9%994
30. Eructation1.8%941

Top 30 of 2,204 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 18 drugs in the glp-1 receptor agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 404,853 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 86.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 52,881 reports.

Drugs most often listed in the same reports

Other products listed in reports where Ozempic is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the glp-1 receptor agonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Ozempic as a suspect or interacting product; reports listing it only as a concomitant medication (13,159) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.